Patient-Derived Models in Glioblastoma Research

Patient-derived models have transformed glioblastoma research by preserving the genetic, epigenetic and microenvironmental complexity of individual tumours. Unlike long-established cell lines, which often diverge from primary tumour biology through genetic drift and loss of phenotypic heterogeneity, models derived directly from patient tissue—such as three-dimensional organoids, orthotopic xenografts and slice cultures—maintain inter- and intratumour diversity. These systems facilitate functional interrogation of therapy resistance, tumour–stroma interactions and cellular hierarchies, including glioblastoma stem-like cells. By enabling high-throughput drug screening, single-cell profiling and in vivo validation in immunodeficient hosts, patient-derived platforms bridge the gap between molecular discovery and clinical application, offering a more predictive avenue for biomarker development and personalised therapy.

Research from Nature Portfolio

Recent studies have introduced advanced three-dimensional heterotypic brain sphere platforms in which patient-derived glioblastoma cells are co-cultured with induced pluripotent stem cell-derived neurons and glia. These spheroids faithfully retain tumour-specific mutations and cell-type composition, enabling parallel assessment of tumour cytotoxicity and neuronal toxicity across panels of approved and experimental agents. The platform generates quantitative dose-response metrics, demonstrating concordance with patient outcomes and offering a rapid functional assay for personalised drug selection. In parallel, novel organoid systems grown in synthetic hydrogel matrices capture patient-specific transcriptomic states over extended passages, preserving spatial microarchitecture and permitting targeted genome editing. These organoids support precision testing of pathway inhibitors and immunomodulatory approaches, underscoring their potential as predictive avatars in translational research.

Patient-Derived Models in Glioblastoma Research publication trend

The graph below shows the total number of articles in patient-derived models in glioblastoma research across all publications each year (not limited to Nature Index journals).

Technical terms

Organoid: A three-dimensional cellular assembly derived from patient tumour cells that self-organises to mimic key structural and functional features of the original tissue.

Orthotopic xenograft: Transplantation of patient-derived tumour cells into the anatomically appropriate location of an immunodeficient animal to study tumour growth in a native microenvironment.

Patient-derived xenograft (PDX): A model in which fresh human tumour fragments are engrafted into immunocompromised mice, preserving tumour heterogeneity and stromal components across passages.

Organotypic slice culture: An ex vivo platform in which freshly resected brain tumour tissue is maintained on living brain slices to study cell interactions and drug responses in situ.

Glioblastoma stem-like cells (GSCs): A subpopulation within glioblastoma characterised by self-renewal capacity, tumour initiation potential and resistance to standard therapies.

References

1. U‐251 revisited: genetic drift and phenotypic consequences of long‐term cultures of glioblastoma cells. Cancer Medicine (2014).
2. A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Scientific Reports (2019).
3. A living ex vivo platform for functional, personalized brain cancer diagnosis. Cell Reports Medicine (2023).
4. Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer Cell (2022).
5. Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas. Cancer Cell International (2020).
6. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica (2020).